Monotherapy for patients w/ metastatic breast cancer, where there is an increased cardiac risk. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemotherapy regimen. In combination w/ bortezomib for the treatment of progressive multiple myeloma in patients who have received at least 1 prior therapy & who have already undergone or are unsuitable for bone marrow transplant. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts (<200 CD4 lymphocytes/mm3
) & extensive mucocutaneous or visceral disease. 1st-line systemic chemotherapy or as 2nd line chemotherapy in AIDS-KS patients w/ disease that has progressed w/, or in patients intolerant to, prior combination systemic chemotherapy comprising at least 2 of the following agents: vinca alkaloid, bleomycin & standard doxorubicin (or other anthracycline).